lundi 18 novembre 2019

Onco Actu du 18 novembre 2019


3. PRÉVENTION



Eliminating Common Bacterial Infection Significantly Decreases Gastric Cancer Risk [Penn Medicine]











3.1.1 PRÉVENTION - TABAC - E-CIGS



While American Heart Association Claims E-Cigarettes are as Harmful as Smoking, a Clinical Trial Shows Immediate Cardiovascular Improvement After Smokers Switched to E-Cigarettes [The Rest of the Story]










Apple to Ban Vaping Apps From Its Store [NY Times]










Smokers who switch to vaping rapidly boost heart health in trial [Reuters]











Apple removes vaping apps from App Store [CNN]











Trump Retreats From Flavor Ban for E-Cigarettes [NY Times]











4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC



Nudge Increases Cancer Screening Orders, But Patient-Facing Nudge Needed, Too [Penn Medicine]










5.1 TRAITEMENTS - PRÉ-CLINIQUE



Tracking How a Breast Cancer Drug Works Points to a Possible New Therapy [Duke Health]











5.12.11 IMMUNOTHÉRAPIES - PRÉ-CLINIQUE



Advanced bowel cancers have very few ‘molecular flags’, hindering immune recognition [Institute of Cancer Research]











5.12.8 IMMUNOTHÉRAPIES - ECONOMIE



CAR T-cell Therapy Causes Heavy Financial Losses for Hospitals [Medscape]











5.2.2 PHARMA - FUSIONS & ACQUISITIONS



FTC clears Bristol-Myers’ $74B deal to buy Celgene — but Dems signal a potential hard shift against Big Pharma M&A [EndPoints]











5.2.3 PHARMA - ÉCONOMIE



BeiGene nabs landmark FDA nod for Brukinsa, kicking off challenge against blockbuster Imbruvica [Fierce Pharma]











BeiGene FDA cancer drug nod seen as breakthrough for Chinese biopharma [Biopharma Dive]











5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)



Celgene Receives CHMP Positive Opinion for REVLIMID® (lenalidomide) in Combination With Rituximab for the Treatment of Adult Patients With Previously Treated Follicular Lymphoma [Celgene]











CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma [Roche]











CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neoadjuvant treatment [Roche]











Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 11-14 November 2019 [EMA]










5.7.1 SABCS-COMMUNIQUÉS



Roche to present new and updated data for seven approved and investigational medicines across multiple types of breast cancer at the 2019 San Antonio Breast Cancer Symposium [Roche]











6. LUTTE CONTRE LES CANCERS



Advances in Lung Cancer Research and Treatment [Cancer Research Catalyst]











6.1 OBSERVATION



NHS staff shortages put 'cancer survival rates at risk' [BBC News]











6.9 CONTROVERSES



Noorchashm: “Biopsy your tumors”—with failed fibroid guidelines, gynecologists might as well be reading tea leaves [The Cancer Letter]